Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease.
about
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative DisordersCytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathiesThe chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's diseaseMitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current conceptsShaping the role of mitochondria in the pathogenesis of Huntington's diseasePartial complex I deficiency due to the CNS conditional ablation of Ndufa5 results in a mild chronic encephalopathy but no increase in oxidative damage.Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies.Mouse models of Huntington's disease and methodological considerations for therapeutic trials.Synergy between chronic corticosterone and sodium azide treatments in producing a spatial learning deficit and inhibiting cytochrome oxidase activity.Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?Bioenergetics in Huntington's disease.Reduced creatine kinase as a central and peripheral biomarker in Huntington's diseaseThe neurodegenerative mitochondriopathies.Mitochondrial loss, dysfunction and altered dynamics in Huntington's diseasePlatelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism.Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.Oxidative stress in neurodegenerationDoes impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?Huntington's disease and neurotoxins.The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains.An introduction to the free radical hypothesis in Parkinson's disease.Normal platelet mitochondrial complex I activity in Huntington's disease.Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia.The mitochondrial energy transduction system and the aging process.Mitochondria in neurodegeneration.Mitochondria and neurodegeneration.Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease.Mechanisms of neurodegeneration in Huntington's disease.Mitochondrial approaches for neuroprotectionOxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly.Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.The respiratory-chain NADH dehydrogenase (complex I) of mitochondria.Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease.Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of diseasePlatelet mitochondrial function: from regulation of thrombosis to biomarker of disease.Acidosis during reoxygenation has an early detrimental effect on neuronal metabolic activity.Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology.A controlled trial of idebenone in Huntington's disease.Toward understanding the molecular pathology of Huntington's disease.
P2860
Q26775096-B80A510B-8180-4CCB-AB94-3BC44D9D183FQ26859496-E27983CF-E2E4-4420-93CA-9665AB64F3B5Q28072937-70509A42-5C81-4C2F-BF19-9B3EF45E7D49Q28251780-DEBD2F7E-F602-4DC7-914A-5D010646F40CQ28384036-89E0F286-C5E4-44D5-88A6-F68CD3096F3AQ28587077-5BF7A97D-7F06-41ED-8861-F141C8B6D0C8Q30442688-132FD99B-5A3A-4769-931E-E9AB919A86C7Q30481208-173EF1B8-7848-4DFE-9303-374520CD6608Q33558336-A5DF6859-55FB-488F-8220-53CAB52C1E67Q33619310-AE89390E-020D-48A1-9B47-0E21BA8F718CQ33836239-FAB99B1F-B853-4EB0-8D23-BDBF910C29A9Q33945688-48570709-5815-4684-9236-3E121D647BD8Q33957065-3DBC0006-296B-4B48-B513-97AE5FCC9214Q34163054-674469DC-71E5-4C01-981C-C9768D206598Q34627459-F17B6451-EBEA-410E-8DEA-546E97AE691CQ34756401-87695B51-DFF9-4636-8060-F8513A53B4F2Q35161675-6D9713AC-6360-4440-9720-1F7D4ADECAA9Q35224677-33DF52D7-C1DA-4505-8021-FAD02F0B1B1EQ35254212-DF0461BF-C40A-4ACA-9F0B-778E2DBA0E8BQ35346684-66A7351F-086D-4EC6-9E51-305CBA0B93FAQ35620962-14243C50-5EF1-4E34-9AFA-D796C975860EQ35753876-7D2B814B-8039-43BA-B633-443A7372FD31Q36274461-F5F99B8D-5CFC-47FE-AAC7-E20B089BC520Q36557236-EA5EB5AA-77E6-4749-9FED-52C88852B69DQ36614262-467300E5-7EBF-4702-9E40-7181DBA42300Q36745271-DB40D6A8-074F-442C-A453-1240BCA201AFQ36814477-DF48F5CE-21ED-418D-BFD2-94B2FA5A0677Q37157528-D7CCFB2C-B26B-4B7E-88FF-16E70E1BB5FFQ37202865-A141EFC7-75A2-41EB-BAD4-920A335B4FA3Q37348590-062C9F87-FBB4-4614-B7D3-CEB628C16473Q37643688-5DBFAFF0-7455-4ACF-8C25-7ADCA69CACAFQ37689883-F6D05519-B55D-40E6-B514-5ED1F26C6B16Q37714057-C54E0FF1-F979-482F-BF92-17B6E586747BQ37750542-68B956C6-5FE3-496B-BD10-20D79A853BA5Q37996350-87A71C42-51DC-46F8-B3CB-4B45EE8E8133Q38077217-E2ED19C2-C0EF-45EC-A295-E4A789BC9975Q40461220-237F741E-3B0B-48B0-83A4-354ADBC6F43BQ40619363-76670316-43E2-4A83-8A8F-B3CCF59D5BF7Q40929165-E34142CC-F680-4A82-998D-CAEEDD37E60BQ41527106-28B0FAF3-41BF-46D3-8EE7-BE2DABE77EBF
P2860
Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Evidence for a defect in NADH: ...... ex I) in Huntington's disease.
@en
Evidence for a defect in NADH: ubiquinone oxidoreductase
@nl
type
label
Evidence for a defect in NADH: ...... ex I) in Huntington's disease.
@en
Evidence for a defect in NADH: ubiquinone oxidoreductase
@nl
prefLabel
Evidence for a defect in NADH: ...... ex I) in Huntington's disease.
@en
Evidence for a defect in NADH: ubiquinone oxidoreductase
@nl
P2093
P356
P1433
P1476
Evidence for a defect in NADH: ...... ex I) in Huntington's disease.
@en
P2093
P304
P356
10.1212/WNL.40.8.1231
P407
P577
1990-08-01T00:00:00Z